Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

High dose diazepam in schizophrenia.

H Beckmann, S Haas

    Psychopharmacology
    |January 1, 1980
    PubMed
    Summary
    This summary is machine-generated.

    High-dose diazepam (up to 400 mg/day) showed potential in treating specific schizophrenia symptoms like hallucinations and delusions. Some patients experienced reduced psychopathology, but others did not respond, indicating varied efficacy.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Efficacy and safety of BAY 81-8973, a full-length recombinant factor VIII: results from the LEOPOLD I trial.

    Haemophilia : the official journal of the World Federation of Hemophilia·2016
    Same author

    BAY 81-8973, a full-length recombinant factor VIII: results from an International comparative laboratory field study.

    Haemophilia : the official journal of the World Federation of Hemophilia·2016
    Same author

    Chromogenic assay for BAY 81-8973 potency assignment has no impact on clinical outcome or monitoring in patient samples.

    Journal of thrombosis and haemostasis : JTH·2016
    Same author

    Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme.

    Haemophilia : the official journal of the World Federation of Hemophilia·2016
    Same author

    Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II).

    Journal of thrombosis and haemostasis : JTH·2014
    Same author

    Late spontaneous recanalization of a symptomatically occluded internal carotid artery two years after extra-intracranial bypass. Case report and review of the literature.

    The Journal of cardiovascular surgery·2012
    Same journal

    Effects of repeated treatment with opioids that vary in mu opioid receptor efficacy on pain-depressed locomotor behavior in mice.

    Psychopharmacology·2026
    Same journal

    Cannabidiol in the anterior insular cortex attenuates chronic neuropathic pain and comorbid anxiety- and depression-like behaviors: involvement of CB<sub>1</sub> and 5-HT<sub>1A</sub> receptor signaling.

    Psychopharmacology·2026
    Same journal

    Fentanyl decreases arterial blood oxygen saturation more than furanylfentanyl in mice due to increased apnea.

    Psychopharmacology·2026
    Same journal

    Suicide attempt risk among patients receiving methylphenidate: a retrospective cohort study.

    Psychopharmacology·2026
    Same journal

    Investigating the impact of serotonergic psychedelic drugs, MDMA and ketamine on social cognition in psychiatric disorders: A scoping review.

    Psychopharmacology·2026
    Same journal

    OPRD1 rs4654327 and Outcomes of Extended-Release Naltrexone in Alcohol Use Disorder: An Exploratory Prospective Pharmacogenetic Study.

    Psychopharmacology·2026
    See all related articles

    Area of Science:

    • Psychiatry
    • Pharmacology

    Background:

    • Diazepam's pharmacological profile and debated antipsychotic effects prompted re-evaluation.
    • Previous research indicated equivocal antipsychotic properties of diazepam.

    Purpose of the Study:

    • To assess the efficacy of high-dose diazepam in schizophrenic patients.
    • To re-evaluate diazepam's usefulness in treating schizophrenia.

    Main Methods:

    • Fifteen schizophrenic patients received diazepam up to 400 mg/day.
    • Psychopathology was assessed using the Brief Psychiatric Rating Scale (BPRS) and Global Clinical Impressions (GCI).

    Main Results:

    • Significant psychopathology reduction observed in 10 patients (paranoid-hallucinatory and schizo-affective psychosis).

    Related Experiment Videos

  • Five schizo-affective patients with depressive or anxiety symptoms did not respond and were withdrawn.
  • Absence of sedation, with some patients reporting well-being and euphoria; disinhibition noted in three patients at high doses.

    • Conclusions:

    • High-dose diazepam may benefit specific subtypes of schizophrenia.
    • Patient response to high-dose diazepam varies, suggesting targeted application.